75.00Open75.00Pre Close0 Volume61 Open Interest185.00Strike Price0.00Turnover64.08%IV2.74%PremiumDec 20, 2024Expiry Date68.07Intrinsic Value100Multiplier19DDays to Expiry6.93Extrinsic Value100Contract SizeAmericanOptions Type0.9875Delta0.0009Gamma3.69Leverage Ratio-0.0516Theta0.0933Rho3.64Eff Leverage0.0185Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet